Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis (Q38417421)

2 September 2017

Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis (English)

1 reference

2 September 2017

1 reference

5

Jaakko Tuomilehto

0 references

Samira Bell

Samira Bell

2

0 references

Helen M. Colhoun

Helen M Colhoun

24

0 references

Andrew G. Renehan

Andrew G Renehan

9

0 references

Reijo Sund

Reijo Sund

3

0 references

Thomas Macdonald

Thomas M MacDonald

21

0 references

Jeffrey A Johnson

Jeffrey A Johnson

15

0 references

Iain Buchan

Iain E Buchan

10

0 references

Eero Pukkala

6

Eero Pukkala

1 reference

2 September 2017

18

Albert Hofman

1 reference

2 September 2017

Daniel Levin

1

1 reference

2 September 2017

Sirpa A Hartikainen

4

1 reference

2 September 2017

Ilmo Keskimäki

7

1 reference

2 September 2017

Ellena Badrick

8

1 reference

2 September 2017

Samantha L Bowker

11

1 reference

2 September 2017

Jasjeet K Minhas-Sandhu

12

1 reference

2 September 2017

Zafar Zafari

13

1 reference

2 September 2017

Carlo Marra

14

1 reference

2 September 2017

Bruno H Stricker

16

1 reference

2 September 2017

Andrè G Uitterlinden

17

1 reference

2 September 2017

Rikje Ruiter

19

1 reference

2 September 2017

Catherine E de Keyser

20

1 reference

2 September 2017

Sarah H Wild

22

1 reference

2 September 2017

Paul M McKeigue

23

1 reference

2 September 2017

Scottish Diabetes Research Network Epidemiology Group

25

1 reference

2 September 2017

Diabetes and Cancer Research Consortium

26

1 reference

2 September 2017

language of work or name

1 reference

7 December 2014

1 reference

2 September 2017

1 reference

2 September 2017

58

1 reference

2 September 2017

493-504

1 reference

2 September 2017

3

1 reference

https://scigraph.springernature.com/pub.10.1007/s00125-014-3456-9

2 September 2017

0 references

cites work

Diabetes mellitus and risk of bladder cancer: a meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3456-9

Expression of peroxisome proliferator-activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3456-9

Role of peroxisome proliferator-activated receptor gamma and its ligands in non-neoplastic and neoplastic human urothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3456-9

Effects of pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, on the urine and urothelium of the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3456-9

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3456-9

Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3456-9

Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3456-9

The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3456-9

Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3456-9

Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3456-9

Risk of bladder cancer in diabetic patients treated with rosiglitazone or pioglitazone: a nested case–control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3456-9

Pioglitazone use and the risk of bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3456-9

Diabetes and risk of bladder cancer: evidence from a case-control study in New England

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3456-9

Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3456-9

The risk of bladder cancer in korean diabetic subjects treated with pioglitazone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3456-9

Pioglitazone and bladder cancer: a population-based study of Taiwanese.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3456-9

Pioglitazone and bladder cancer: a propensity score matched cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3456-9

Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3456-9

A review on thiazolidinediones and bladder cancer in human studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3456-9

Metformin and the risk of cancer: time-related biases in observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3456-9

Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3456-9

On the treatment of grouped observations in life studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3456-9

Proteinuria testing among patients with diabetes mellitus is associated with bladder cancer diagnosis: potential for unmeasured confounding in studies of pioglitazone and bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3456-9

Diabetes and risk of bladder cancer: a study using the National Health Insurance database in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3456-9

Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3456-9

Pathology of bladder cancer among diabetic patients undergoing radical cystectomy with a history of pioglitazone (Actos) use

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3456-9

Possible link of pioglitazone with bladder cancer in Japanese patients with type 2 diabetes

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25481707

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Rosiglitazone is not associated with an increased risk of bladder cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25481707

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Pioglitazone and bladder cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25481707

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S00125-014-3456-9

1 reference

Dimensions Publication ID

2 September 2017

0 references

1 reference